Is Immunogen Done After This Ovarian Cancer Study?

Health and Healthcare

Published: March 1, 2019 10:15 am

Last Updated: January 31, 2020 12:03 am

ImmunoGen Inc. (NASDAQ: IMGN) shares were halved on Friday after the firm reported late-stage results from its ovarian cancer study.

Specifically, the results from its Phase 3 Forward 1 trial evaluating the safety and efficacy of mirvetuximab soravtansine compared to chemotherapy in patients with folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer.

Ultimately, the trial did not meet its primary endpoint of progression-free surviva in either the entire study population or in the prespecified subset of patients with high FRα expression. The primary endpoint was assessed using the Hochberg procedure in the entire study population and in the subset of patients with high FRα expression.

The firm did not have much to say about what it has planned in the future except that it intends to present additional results from Forward 1 at an upcoming medical meeting.

Dr. Kathleen Moore, associate director of Clinical Research at the Stephenson Cancer Center at the University of Oklahoma, commented:

Even though FORWARD I did not meet its primary endpoint, I continue to be impressed with the efficacy and tolerability of mirvetuximab soravtansine in ovarian cancer patients, especially in the subset with high FRα expression. I look forward to continuing to work with ImmunoGen to analyze the Phase 3 data and determine the most appropriate path to bringing mirvetuximab soravtansine to those patients who benefit most from it.

Shares of ImmunoGen were last seen down 49% at $2.41, in a 52-week range of $2.27 to $13.41.

24/7 Wall St.
5 Safe Merrill Lynch US 1 List Stocks to Buy That Pay Big Dividends

Travel Cards Are Getting Too Good To Ignore (sponsored)

Credit card companies are pulling out all the stops, with the issuers are offering insane travel rewards and perks.

We’re talking huge sign-up bonuses, points on every purchase, and benefits like lounge access, travel credits, and free hotel nights. For travelers, these rewards can add up to thousands of dollars in flights, upgrades, and luxury experiences every year.

It’s like getting paid to travel — and it’s available to qualified borrowers who know where to look.

We’ve rounded up some of the best travel credit cards on the market. Click here to see the list. Don’t miss these offers — they won’t be this good forever.